NYSEAMERICAN:MYO Myomo (MYO) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free MYO Stock Alerts $3.76 -0.16 (-4.08%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$3.65▼$4.1950-Day Range N/A52-Week Range$0.37▼$5.58Volume446,396 shsAverage Volume354,141 shsMarket Capitalization$108.29 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest Get Myomo alerts: Email Address Myomo MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside72.9% Upside$6.50 Price TargetShort InterestHealthy3.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingAcquiring Shares$175,000 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.18) to ($0.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.19 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMyomo has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMyomo has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.08% of the float of Myomo has been sold short.Short Interest Ratio / Days to CoverMyomo has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Myomo has recently decreased by 3.53%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMyomo does not currently pay a dividend.Dividend GrowthMyomo does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MYO. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Myomo this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myomo insiders have bought more of their company's stock than they have sold. Specifically, they have bought $175,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of Myomo is held by insiders.Percentage Held by Institutions44.99% of the stock of Myomo is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Myomo are expected to grow in the coming year, from ($0.18) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myomo is -13.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myomo is -13.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyomo has a P/B Ratio of 11.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About Myomo Stock (NYSEAMERICAN:MYO)Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.Read More MYO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MYO Stock News HeadlinesMay 2, 2024 | finance.yahoo.comMyomo, Inc. (MYO) Stock Price, News, Quote & History - Yahoo FinanceMay 1, 2024 | businesswire.comMyomo to Report First Quarter Financial Results on May 8, 2024May 4, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 20, 2024 | finance.yahoo.comMyomo, Inc. (MYO)March 30, 2024 | investing.comMyomo appoints Heather Getz to board of directorsMarch 28, 2024 | businesswire.comMyomo Appoints Heather Getz to its Board of DirectorsMarch 28, 2024 | businesswire.comMyomo Appoints Heather Getz to its Board of DirectorsMarch 18, 2024 | ca.sports.yahoo.comColby Covington reacts to Jorge Masvidal vs. Nate Diaz boxing match: ‘Sloppy, old f*cking dudes’May 4, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)March 18, 2024 | finance.yahoo.comDirector Thomas Kirk Acquires 50,000 Shares of Myomo Inc (MYO)March 13, 2024 | seekingalpha.comMyomo's Revolutionary MyoPro Brace: A Buy In Neurological Mobility AidMarch 10, 2024 | seekingalpha.comMyomo, Inc.: In Motion To Accelerating Revenue GrowthMarch 9, 2024 | seekingalpha.comMyomo, Inc. (MYO) Q4 2023 Earnings Call TranscriptMarch 9, 2024 | markets.businessinsider.comMyomo Inc.: Strong Growth and Regulatory Tailwinds Support Buy RatingMarch 8, 2024 | finance.yahoo.comMyomo, Inc. (AMEX:MYO) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | investorplace.comMYO Stock Earnings: Myomo Misses EPS, Misses Revenue for Q4 2023March 7, 2024 | msn.comMyomo GAAP EPS of -$0.07 misses by $0.01, revenue of $4.76M misses by $0.06MMarch 7, 2024 | businesswire.comMyomo Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | msn.comMyomo Q4 2023 Earnings PreviewMarch 6, 2024 | finance.yahoo.comMYO Mar 2024 7.500 callMarch 6, 2024 | benzinga.comMyomo Earnings PreviewMarch 6, 2024 | markets.businessinsider.comHere's what Wall Street expects from Myomo's earningsMarch 1, 2024 | finance.yahoo.comCMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro®February 29, 2024 | businesswire.comMyomo to Report Fourth Quarter Financial Results on March 7, 2024February 28, 2024 | finance.yahoo.comMyomo, Inc. (MYO) Stock Historical Prices & Data - Yahoo FinanceJanuary 19, 2024 | finance.yahoo.comMyomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-MarketJanuary 17, 2024 | marketwatch.comMyomo Stock Rises 6% After 4Q Preliminary ResultsSee More Headlines Receive MYO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myomo and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Surgical appliances & supplies Sub-IndustryN/A Current SymbolNYSEAMERICAN:MYO CUSIPN/A CIK1369290 Webmyomo.com Phone(617) 996-9058FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$6.50 Low Stock Price Target$6.50 Potential Upside/Downside+72.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,150,000.00 Net Margins-42.34% Pretax Margin-41.54% Return on Equity-84.72% Return on Assets-55.55% Debt Debt-to-Equity RatioN/A Current Ratio2.49 Quick Ratio2.16 Sales & Book Value Annual Sales$19.24 million Price / Sales5.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book11.06Miscellaneous Outstanding Shares28,800,000Free Float27,877,000Market Cap$108.29 million OptionableNot Optionable Beta1.51 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Paul R. Gudonis (Age 69)Chairman, President & CEO Comp: $526.56kMr. David A. Henry (Age 63)Chief Financial Officer Comp: $401.56kDr. Harry Kovelman M.D. (Age 65)Chief Medical Officer Comp: $426.03kColin AndersonGlobal Director of OperationsMr. Joseph ChicoskieDirector of MarketingMs. Galina ShtivelmanSenior Director of Human ResourcesMr. Micah J. Mitchell (Age 48)Chief Commercial Officer Comp: $317.39kMore ExecutivesKey CompetitorsEnvoy MedicalNASDAQ:COCHCollPlant BiotechnologiesNASDAQ:CLGNVicarious SurgicalNYSE:RBOTMilestone ScientificNYSE:MLSSUnited Health ProductsOTCMKTS:UEECView All CompetitorsInsiders & InstitutionsEssex Investment Management Co. LLCBought 508,249 shares on 5/3/2024Ownership: 2.093%Rosalind Advisors Inc.Bought 527,830 shares on 4/25/2024Ownership: 8.592%Accel Wealth ManagementBought 41,382 shares on 4/19/2024Ownership: 0.145%Thomas F KirkBought 50,000 shares on 3/14/2024Total: $175,000.00 ($3.50/share)Summit Financial Strategies Inc.Bought 10,000 shares on 2/13/2024Ownership: 0.038%View All Insider TransactionsView All Institutional Transactions MYO Stock Analysis - Frequently Asked Questions Should I buy or sell Myomo stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MYO shares. View MYO analyst ratings or view top-rated stocks. What is Myomo's stock price target for 2024? 2 equities research analysts have issued 12-month target prices for Myomo's stock. Their MYO share price targets range from $6.50 to $6.50. On average, they predict the company's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 72.9% from the stock's current price. View analysts price targets for MYO or view top-rated stocks among Wall Street analysts. How have MYO shares performed in 2024? Myomo's stock was trading at $4.74 at the beginning of the year. Since then, MYO stock has decreased by 20.7% and is now trading at $3.76. View the best growth stocks for 2024 here. How were Myomo's earnings last quarter? Myomo, Inc. (NYSEAMERICAN:MYO) posted its quarterly earnings data on Thursday, March, 7th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.02. The firm earned $4.76 million during the quarter, compared to analysts' expectations of $4.70 million. Myomo had a negative net margin of 42.34% and a negative trailing twelve-month return on equity of 84.72%. What guidance has Myomo issued on next quarter's earnings? Myomo updated its first quarter 2024 earnings guidance on Thursday, March, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.1 million-$4.3 million, compared to the consensus revenue estimate of $4.5 million. What other stocks do shareholders of Myomo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myomo investors own include Genocea Biosciences (GNCA), Agile Therapeutics (AGRX), Sarepta Therapeutics (SRPT), Aclaris Therapeutics (ACRS), Remark (MARK), Synergy Pharmaceuticals (SGYP), VBI Vaccines (VBIV), Athersys (ATHX) and Anavex Life Sciences (AVXL). Who are Myomo's major shareholders? Myomo's stock is owned by many different retail and institutional investors. Top institutional shareholders include Rosalind Advisors Inc. (8.59%), Essex Investment Management Co. LLC (2.09%) and Accel Wealth Management (0.15%). Insiders that own company stock include David A Henry, Harry Kovelman, Micah Mitchell, Milton Mayo Morris, Paul R Gudonis, Thomas Aloysius Jr Crowley and Thomas F Kirk. View institutional ownership trends. How do I buy shares of Myomo? Shares of MYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:MYO) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe Gold Grab of the CenturyColonial Metals4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myomo, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.